Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01019317 | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01461538 | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | completed | Phase 2 | 84 | Seagen Inc.INDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00850382 |
| Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) |
| completed |
| Phase 1 / Phase 2 |
| 89 |
| University of UlmOTHER |
| 2 |
| Mar 1, 2016 |
| clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia(Aza-E) | completed | Phase 2 | 25 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00893373 | Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age(SORAML) | completed | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT00188136 | Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) | completed | Phase 2 | 32 | University Hospital Carl Gustav CarusOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00062075 | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00491634 | Treosulfan-based Conditioning for Transplantation in AML/MDS | completed | Phase 2 | 24 | Dr. Avichai Shimoni MDOTHER_GOV | 1 | Dec 2, 2015 | clinicaltrials |
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00957385 | Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients | completed | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01361464 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00924443 | A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | completed | Phase 2 | 69 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Apr 1, 2015 | clinicaltrials |
| NCT00098033 | Investigation of Clofarabine in Acute Leukemias | completed | Phase 2 | 64 | University of TexasOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00656617 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 2 | 106 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 8, 2014 | clinicaltrials |
| NCT02182596 | DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML(MYLOFRANCE2) | completed | Phase 1 / Phase 2 | 20 | Acute Leukemia French AssociationOTHER | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01236144 | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.(AML18 Pilot) | completed | Phase 1 / Phase 2 | 113 | Cardiff UniversityOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00130702 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | May 1, 2014 | clinicaltrials |
| NCT00315705 | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | completed | Phase 1 / Phase 2 | 50 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00373529 | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) | completed | Phase 2 | 116 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT02113319 | Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia(DasaCBF) | completed | Phase 2 | 27 | University Hospital, AngersOTHER_GOV | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00044889 | Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00774046 | High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | completed | Phase 2 | 32 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00016016 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT01035502 | A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia | completed | Phase 2 | 51 | Clavis PharmaINDUSTRY | 4 | Sep 27, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00882102 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2016source: clinicaltrials